CORT (Corcept Therapeutics) EPS without NRI: $0.35 (TTM As of Mar. 2026)


CORT Corcept Therapeutics Inc CORT
85 GF Score
Price $87.68
GF Value $61.67
Valuation Significantly Overvalued
! 8 Warning Signs
View Full Analysis

What is Corcept Therapeutics EPS without NRI?

Corcept Therapeutics CORT -0.24% 85 EPS without NRI is $0.35 as of Mar. 2026. GuruFocus rates CORT with a GF Score™ of 85/100 and a GF Value™ of $61.67 (Significantly Overvalued). The stock has 8 warning signs investors should review. Among 1,172 Biotechnology companies, Corcept Therapeutics ranks worse than 73.46% on this metric.

Corcept Therapeutics's earnings per share without non-recurring items for the three months ended in Mar. 2026 was $-0.30. Its earnings per share without non-recurring items for the trailing twelve months (TTM) ended in Mar. 2026 was $0.35.

During the past 12 months, Corcept Therapeutics's average earnings per share (NRI) Growth Rate was -69.80% per year. During the past 3 years, the average earnings per share (NRI) Growth Rate was -2.00% per year. During the past 5 years, the average earnings per share (NRI) Growth Rate was -4.50% per year. During the past 10 years, the average earnings per share (NRI) Growth Rate was 30.50% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using Earnings per share without Non-Recurring Items (NRI) data.

The historical rank and industry rank for Corcept Therapeutics's EPS without NRI or its related term are showing as below:

CORT' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -7   Med: 11.9   Max: 249
Current: -2

During the past 13 years, Corcept Therapeutics's highest 3-Year average Earnings Per Share (NRI) Growth Rate was 249.00% per year. The lowest was -7.00% per year. And the median was 11.90% per year.

CORT's 3-Year EPS without NRI Growth Rate is ranked worse than
73.46% of 1172 companies
in the Biotechnology industry
Industry Median: 16.8 vs CORT: -2.00

Corcept Therapeutics's EPS (Diluted) for the three months ended in Mar. 2026 was $-0.30. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 was $0.35.

Corcept Therapeutics's EPS (Basic) for the three months ended in Mar. 2026 was $-0.30. Its EPS (Basic) for the trailing twelve months (TTM) ended in Mar. 2026 was $0.45.


Corcept Therapeutics  (NAS:CORT) EPS without NRI Explanation

EPS without NRI removes onetime and unusual items from EPS, to provide investors with a more accurate measure of the company’s true earnings. The earnings are adjusted for items that are irregular or unusual in nature, and/or are non-recurring. This is calculated using Net Income (Continuing Operations) plus/minus any tax affected unusual Items and Goodwill Impairments/Write Offs. This can be used to fairly measure a company's profitability.


Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.


Corcept Therapeutics EPS without NRI Related Terms


Corcept Therapeutics EPS without NRI Historical Data

* Premium members only.

The historical data trend for Corcept Therapeutics's EPS without NRI can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Corcept Therapeutics EPS without NRI Chart

Corcept Therapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
EPS without NRI
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.19 0.87 0.94 1.23 0.82

Corcept Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
EPS without NRI Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.17 0.29 0.16 0.20 -0.30

CORT vs PRAX, IBRX, NUVL: EPS without NRI Comparison

For the Biotechnology subindustry, Corcept Therapeutics's PE Ratio without NRI, along with its competitors' market caps and PE Ratio without NRI data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Corcept Therapeutics PE Ratio without NRI vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Corcept Therapeutics's PE Ratio without NRI distribution charts can be found below:

* The bar in red indicates where Corcept Therapeutics's PE Ratio without NRI falls into.


CORT
85GF Score
Corcept Therapeutics Inc CORT
EPS without NRI is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Corcept Therapeutics EPS without NRI Calculation

Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Earnings Per Share without Non-Recurring Items is the amount of earnings without non-recurring items per outstanding share of the company's stock.

EPS without NRI for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.35

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EPS without NRI →
What does a EPS without NRI of $0.35 mean?
Corcept Therapeutics (CORT) has a EPS without NRI of $0.35 as of Mar. 2026. EPS without NRI represents per-share earnings excluding one-time charges. View historical data on Corcept Therapeutics and its competitors. According to the industry distribution chart, Corcept Therapeutics ranks #861 out of 1172 companies in the Biotechnology industry, placing it in the top 73.5%.
Is Corcept Therapeutics' EPS without NRI too high?
Corcept Therapeutics' current EPS without NRI is $0.35. The Biotechnology industry median EPS without NRI is 16.80. Corcept Therapeutics' value of $0.35 is 97.9% below this industry median. Based on the distribution chart, Corcept Therapeutics ranks #861 out of 1172 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Corcept Therapeutics has a GF Score™ of 85/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Corcept Therapeutics' EPS without NRI compare to PRAX and IBRX?
According to the Biotechnology industry distribution chart, Corcept Therapeutics ranks #861 out of 1172 companies for EPS without NRI. This places Corcept Therapeutics in the lower half of its industry. The industry median EPS without NRI is 16.80. Corcept Therapeutics' value of $0.35 is 97.9% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EPS without NRI for a Biotechnology company?
The median EPS without NRI among Biotechnology companies is 16.80, based on 1,172 companies in the industry. Companies in the top quartile (top 25%) have a EPS without NRI significantly above this median, while those in the bottom quartile fall well below. However, EPS without NRI should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Corcept Therapeutics's current EPS without NRI of $0.35 is 97.9% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EPS without NRI mean?
A high EPS without NRI can signal that a stock is expensive relative to its fundamentals. EPS without NRI represents per-share earnings excluding one-time charges. View historical data on Corcept Therapeutics and its competitors. For the Biotechnology industry, the median EPS without NRI is 16.80 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Corcept Therapeutics's current EPS without NRI is $0.35. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Corcept Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Corcept Therapeutics (CORT) is currently considered Significantly Overvalued. The stock's GF Value™ is $61.67, compared to a current price of $87.68 — trading 42.2% above its estimated fair value. The current EPS without NRI is $0.35 and 97.9% below the Biotechnology industry median of 16.80. Corcept Therapeutics' overall GF Score™ is 85/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EPS without NRI calculated?
EPS without NRI is calculated from a company's financial statements. For Corcept Therapeutics (CORT), the current EPS without NRI is $0.35 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Corcept Therapeutics (CORT) Overvalued in 2026?

Based on GuruFocus' analysis, Corcept Therapeutics stock appears to be overvalued. The current stock price of $87.68 is trading 42.2% above its estimated GF Value™ of $61.67. GuruFocus considers Corcept Therapeutics to be Significantly Overvalued.

Key valuation signals for CORT:

  • EPS without NRI: $0.35
  • GF Value™: $61.67 vs. price of $87.68 (42.2% above fair value)
  • GF Score™: 85/100 with 8 warning signs
  • Industry Position: 97.9% below the Biotechnology median (#861 of 1172)

No single metric tells the full story. See the CORT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Corcept Therapeutics Business Description

Address 101 Redwood Shores Parkway, Redwood City, CA, USA, 94065
Corcept Therapeutics Inc is a commercial-stage pharmaceutical company engaged in the discovery and development of medications that treat severe metabolic, oncologic, and neuropsychiatric disorders by modulating the effect of the cortisol hormone. The company markets Korlym (mifepristone) tablets and its authorized generic version, which is an oral medication for the treatment of hypercortisolism (also known as Cushing's syndrome). Additionally, its pipeline contains several key compounds, such as Relacorilant, Dazucorilant, Miricorilant, etc., that are being evaluated in clinical trials as potential treatments for a variety of serious disorders like hypercortisolism, solid tumors (including ovarian, endometrial, cervical, pancreatic, and prostate cancers), ALS, and MASH.
85GF Score

Get the complete analysis for CORT

EPS without NRI is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$87.68
Price
$61.67
GF Value